Celularity
CELU
56 hedge funds and large institutions have $18.8M invested in Celularity in 2023 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 7 increasing their positions, 20 reducing their positions, and 19 closing their positions.
17,300% more call options, than puts
Call options by funds: $174K | Put options by funds: $1K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.41% less ownership
Funds ownership: 2.37% → 1.96% (-0.41%)
8% less funds holding
Funds holding: 61 → 56 (-5)
12% less capital invested
Capital invested by funds: $21.3M → $18.8M (-$2.53M)
26% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 19
65% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$2.97M |
| 2 |
Millennium Management
New York
|
+$493K |
| 3 |
Renaissance Technologies
New York
|
+$124K |
| 4 |
HF
HRT Financial
New York
|
+$89.7K |
| 5 |
YIH
Y-Intercept (HK)
Hong Kong
|
+$68.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.67M |
| 2 |
State Street
Boston,
Massachusetts
|
-$403K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$248K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$242K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$181K |
CELU Hedge Fund Activity: Q2 2023 in Review
56 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Celularity (CELU) for Q2 2023, worth a combined $18.8M — down 12% from $21.3M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of CELU and 14 opened new positions — a net loss of 5 holders — while 20 trimmed existing stakes and 7 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $2.97M. The largest seller was BlackRock, cutting an estimated $1.67M.
- 56 institutional investors held Celularity (CELU) as of Q2 2023, down from 61 in Q1 2023.
- Funds reported $18.8M of Celularity stock for Q2 2023, down 12% quarter-over-quarter.
- 14 funds opened new Celularity positions in Q2 2023 and 19 closed out, a net change of -5 holders.
- The largest Celularity buyer in Q2 2023 was Armistice Capital, an estimated $2.97M added.
- The largest Celularity seller in Q2 2023 was BlackRock, an estimated $1.67M sold.
Based on aggregated 13F filings for Q2 2023.